Zhongguancun disclosed an earnings forecast, expecting a net loss attributable to the parent of 25 million to 30 million yuan in the first half of 2026, compared with a profit of 38.8089 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 28 million to 33 million yuan, compared with a profit of 36.8549 million yuan in the same period last year. The company stated that the change in performance was mainly due to its core product, benidipine hydrochloride tablets, entering the implementation phase of the eleventh batch of national centralized drug procurement. Affected by the centralized procurement policy, the unit selling price of this product dropped significantly and sales volume declined, causing a substantial impact on operating revenue and operating profit. To cope with the impact, the company is focusing on deepening non-centralized procurement channels, promoting the retail growth of prescription drugs. Strategic products such as oxycodone injection and compound pancreatin powder are rapidly increasing in volume, while the over-the-counter business has achieved notable results in the layout of new retail omni-channels.
Beijing Centergate Technologies Holding Co LtdCore product benidipine hydrochloride tablets hit by national centralized drug procurement policy, causing price drop and sales decline, leading to net loss.